眼筋麻痺の世界市場レポート 2025年

眼筋麻痺の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.1％で27億2,000万米ドルに成長します。予測期間中の成長は、神経疾患の有病率の上昇、高齢化人口の増加、眼球運動障害に対する意識の高まり、医療費の増加、主要企業による医療への投資の増加、糖尿病や高血圧の患者人口の増加などに起因しています。この期間の主要動向としては、診断技術の発展、新規治療アプローチの開発、戦略的提携やパートナーシップ、視線追跡装置の技術革新、筋力強化薬の開発などが挙げられます。

神経疾患の罹患率の増加が眼筋麻痺市場の成長を牽引すると予想されます。神経疾患は、脳、脊髄、神経などの神経系に影響を与え、筋力低下、協調運動障害、認知障害などの症状を引き起こします。これらの疾患の有病率が上昇している背景には、アルツハイマー病やパーキンソン病などの疾患にかかりやすくなる遺伝的要因や、神経変性や認知機能低下の原因となる食生活の乱れ、運動不足、慢性的なストレスなどのライフスタイルの変化があります。眼筋麻痺は、神経系の機能障害を示す眼筋制御障害を特定することで、アルツハイマー病、多発性硬化症、脳卒中などの神経疾患の診断に一役買っています。例えば、2023年3月、米国を拠点とする非営利団体であるアルツハイマー病協会（Alzheimer's Association）は、65歳以上の米国人のうち670万人がアルツハイマー型認知症を患っていると報告し、この数は2060年までに1,380万人に増加すると推定しています。その結果、神経疾患の有病率の増加が眼筋麻痺市場の成長に寄与しています。

眼筋麻痺市場の成長は、自己免疫疾患の有病率の上昇によっても後押しされています。自己免疫疾患は、免疫系が誤って体内の健康な細胞を攻撃し、炎症や組織損傷を引き起こすことで発生します。このような病気は、免疫系が機能不全に陥りやすい遺伝的要因と、感染症、ストレス、生活習慣などの環境的要因が組み合わさって、より一般的になってきています。眼筋麻痺は、自己免疫疾患の診断に特に役立ちます。なぜなら、基礎にある免疫系の問題を特定するのに役立ち、筋麻痺と自己免疫疾患の両方に対処する標的治療を可能にするからです。例えば、2024年11月、ドイツを拠点とする団体Versorgungsatlas.deは、2022年に7,324万1,305人の被保険者のうち630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％と報告しました。その結果、自己免疫疾患の有病率の上昇が眼筋麻痺市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の眼筋麻痺PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の眼筋麻痺市場：成長率分析
• 世界の眼筋麻痺市場の実績：規模と成長、2019～2024年
• 世界の眼筋麻痺市場の予測：規模と成長、2024～2029年、2034年
• 世界の眼筋麻痺総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の眼筋麻痺市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 外眼筋麻痺
• 核間眼筋麻痺
• 世界の眼筋麻痺市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 手術
• 薬剤治療
• 世界の眼筋麻痺市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来クリニック
• 世界の眼筋麻痺市場、外眼筋麻痺のサブセグメンテーション、実績と予測、2019～2024年、2024～2029年、2034年
• 慢性進行性外用眼筋麻痺（CPEO）
• 筋無力症外用眼筋麻痺
• ミトコンドリアミオパチー関連外用眼筋麻痺
• 世界の眼筋麻痺市場、核間眼筋麻痺のサブセグメンテーション、実績と予測、2019～2024年、2024～2029年、2034年
• UINO眼筋麻痺
• BINO眼筋麻痺

第7章 地域別・国別分析

• 世界の眼筋麻痺市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の眼筋麻痺市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 眼筋麻痺市場：競合情勢
• 眼筋麻痺市場：企業プロファイル
  • Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Medline Industries Inc.
  • Regeneron Pharmaceuticals Inc.

第31章 その他の大手企業と革新的企業

• Carl Zeiss AG
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Limited
• Bayer AG
• Santen Pharmaceutical Co. Ltd.
• Oculis Holding AG
• Innovative Pharmaceuticals Pvt. Ltd.
• Clearside Biomedical Inc.
• Altacor Limited
• Azura Ophthalmics Ltd.
• ViGeneron GmbH
• Amritt Inc.
• GenSight Biologics SA
• EyeBio Inc.
• Opthea Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 眼筋麻痺市場、2029年：新たな機会を提供する国
• 眼筋麻痺市場、2029年：新たな機会を提供するセグメント
• 眼筋麻痺市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Ophthalmoplegia refers to the paralysis or weakness of one or more muscles responsible for eye movement. This condition can affect both voluntary and involuntary eye movements and may be caused by neurological disorders, muscle diseases, or vascular conditions.

The main types of ophthalmoplegia include external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia involves the paralysis or weakness of the extraocular muscles, leading to impaired eye movement and drooping eyelids. It is treated with surgery or drug therapy, and the treatments are utilized by end-users such as hospitals, clinics, and ambulatory care centers.

The ophthalmoplegia market research report is one of a series of new reports from The Business Research Company that provides ophthalmoplegia market statistics, including the ophthalmoplegia industry global market size, regional shares, competitors with the ophthalmoplegia market share, detailed ophthalmoplegia market segments, market trends, and opportunities, and any further data you may need to thrive in the ophthalmoplegia industry. This ophthalmoplegia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ophthalmoplegia market size has grown rapidly in recent years. It will grow from $1.68 billion in 2024 to $1.85 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, the expanding aging population, the growth of specialty clinics and hospitals, increasing demand for early diagnosis and treatment, a higher number of clinical trials, and greater healthcare insurance coverage.

The ophthalmoplegia market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth during the forecast period can be attributed to the rising prevalence of neurological disorders, an increasing aging population, growing awareness of eye movement disorders, higher healthcare expenditure, increased investment in healthcare by key players, and a growing patient population with diabetes and hypertension. Key trends during this period include advancements in diagnostic technologies, the development of novel therapeutic approaches, strategic collaborations and partnerships, technological innovations in eye tracking devices, and the development of muscle-strengthening drugs.

The increasing incidence of neurological disorders is expected to drive the growth of the ophthalmoplegia market. Neurological disorders affect the nervous system, including the brain, spinal cord, and nerves, leading to symptoms such as muscle weakness, coordination problems, and cognitive difficulties. The rising prevalence of these disorders is linked to genetic factors, which make individuals more vulnerable to conditions such as Alzheimer's and Parkinson's disease, as well as lifestyle changes such as poor diet, lack of physical activity, and chronic stress, all of which contribute to neurodegeneration and cognitive decline. Ophthalmoplegia plays a role in diagnosing neurological disorders such as Alzheimer's, multiple sclerosis, and stroke by identifying impaired eye muscle control, which indicates dysfunction in the nervous system. For example, in March 2023, the Alzheimer's Association, a U.S.-based nonprofit organization, reported that 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating this number to rise to 13.8 million by 2060. As a result, the increasing prevalence of neurological disorders is contributing to the growth of the ophthalmoplegia market.

The growth of the ophthalmoplegia market is also being fueled by the rising prevalence of autoimmune conditions. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells, leading to inflammation and tissue damage. These diseases are becoming more common due to genetic factors that make some individuals more prone to immune system dysfunction, combined with environmental triggers such as infections, stress, and lifestyle factors. Ophthalmoplegia can be particularly helpful in diagnosing autoimmune disorders, as it helps identify underlying immune system issues and allows for targeted treatments that address both the muscular paralysis and the autoimmune condition. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, 6,304,340 of the 73,241,305 insured individuals were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Consequently, the rising prevalence of autoimmune conditions is driving the growth of the ophthalmoplegia market.

The increasing number of head injuries or trauma cases is expected to further propel the ophthalmoplegia market. Head injuries or trauma refer to damage to the scalp, skull, or brain caused by external forces such as falls, accidents, or impacts. These injuries are becoming more common due to factors such as the rise in road accidents, with high-speed collisions, lack of helmet use, and reckless driving contributing to an increased risk of severe head injuries. Other factors such as workplace accidents, falls, sports injuries, and violence also contribute to the growing incidence of traumatic brain injuries. Ophthalmoplegia can help assess head injuries or trauma by detecting potential neurological damage through impaired eye movement, which allows for early diagnosis and intervention. For instance, in 2023, a report by the Wisconsin Department of Health Services, a U.S. government agency, showed a 3% increase in traumatic injuries caused by assault compared to 2022, with cases rising from 1,544 in 2022 to 1,584 in 2023. As such, the increasing cases of head injuries and trauma are driving the growth of the ophthalmoplegia market.

Major players in the ophthalmoplegia market are Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Medline Industries Inc., Regeneron Pharmaceuticals Inc., Carl Zeiss AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Bayer AG, Santen Pharmaceutical Co. Ltd., Oculis Holding AG, Innovative Pharmaceuticals Pvt. Ltd., Clearside Biomedical Inc., Altacor Limited, Azura Ophthalmics Ltd., ViGeneron GmbH, Amritt Inc., GenSight Biologics SA, EyeBio Inc., Opthea Limited.

North America was the largest region in the ophthalmoplegia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ophthalmoplegia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ophthalmoplegia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ophthalmoplegia market consists of revenues earned by entities by providing services such as diagnosis and imaging services, neurological and ophthalmic evaluations, genetic testing and counselling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The ophthalmoplegia market also includes sales of eye patches and prisms, neuromuscular electrical stimulation (NMES) devices, corticosteroids, immunosuppressants, and botulinum toxin injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ophthalmoplegia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ophthalmoplegia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ophthalmoplegia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ophthalmoplegia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: External Opthalmoplegia; Internuclear Opthalmoplegia
• 2) By Treatment: Surgery; Drug Treatment
• 3) By End-User: Hospitals; Clinics; Ambulatory Clinics
• Sub Segments:
• 1) By External Ophthalmoplegia: Chronic Progressive External Ophthalmoplegia (CPEO); Myasthenic External Ophthalmoplegia; Mitochondrial Myopathy-Associated External Ophthalmoplegia
• 2) By Internuclear Ophthalmoplegia: Unilateral Internuclear Ophthalmoplegia; Bilateral Internuclear Ophthalmoplegia
• Companies Mentioned: Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; Medline Industries Inc.; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ophthalmoplegia Market Characteristics

3. Ophthalmoplegia Market Trends And Strategies

4. Ophthalmoplegia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Ophthalmoplegia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ophthalmoplegia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ophthalmoplegia Market Growth Rate Analysis
• 5.4. Global Ophthalmoplegia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ophthalmoplegia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ophthalmoplegia Total Addressable Market (TAM)

6. Ophthalmoplegia Market Segmentation

• 6.1. Global Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Opthalmoplegia
• Internuclear Opthalmoplegia
• 6.2. Global Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Drug Treatment
• 6.3. Global Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Clinics
• 6.4. Global Ophthalmoplegia Market, Sub-Segmentation Of External Ophthalmoplegia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Progressive External Ophthalmoplegia (CPEO)
• Myasthenic External Ophthalmoplegia
• Mitochondrial Myopathy-Associated External Ophthalmoplegia
• 6.5. Global Ophthalmoplegia Market, Sub-Segmentation Of Internuclear Ophthalmoplegia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Unilateral Internuclear Ophthalmoplegia
• Bilateral Internuclear Ophthalmoplegia

7. Ophthalmoplegia Market Regional And Country Analysis

• 7.1. Global Ophthalmoplegia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ophthalmoplegia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ophthalmoplegia Market

• 8.1. Asia-Pacific Ophthalmoplegia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ophthalmoplegia Market

• 9.1. China Ophthalmoplegia Market Overview
• 9.2. China Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ophthalmoplegia Market

• 10.1. India Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ophthalmoplegia Market

• 11.1. Japan Ophthalmoplegia Market Overview
• 11.2. Japan Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ophthalmoplegia Market

• 12.1. Australia Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ophthalmoplegia Market

• 13.1. Indonesia Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ophthalmoplegia Market

• 14.1. South Korea Ophthalmoplegia Market Overview
• 14.2. South Korea Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ophthalmoplegia Market

• 15.1. Western Europe Ophthalmoplegia Market Overview
• 15.2. Western Europe Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ophthalmoplegia Market

• 16.1. UK Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ophthalmoplegia Market

• 17.1. Germany Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ophthalmoplegia Market

• 18.1. France Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ophthalmoplegia Market

• 19.1. Italy Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ophthalmoplegia Market

• 20.1. Spain Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ophthalmoplegia Market

• 21.1. Eastern Europe Ophthalmoplegia Market Overview
• 21.2. Eastern Europe Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ophthalmoplegia Market

• 22.1. Russia Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ophthalmoplegia Market

• 23.1. North America Ophthalmoplegia Market Overview
• 23.2. North America Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ophthalmoplegia Market

• 24.1. USA Ophthalmoplegia Market Overview
• 24.2. USA Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ophthalmoplegia Market

• 25.1. Canada Ophthalmoplegia Market Overview
• 25.2. Canada Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ophthalmoplegia Market

• 26.1. South America Ophthalmoplegia Market Overview
• 26.2. South America Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ophthalmoplegia Market

• 27.1. Brazil Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ophthalmoplegia Market

• 28.1. Middle East Ophthalmoplegia Market Overview
• 28.2. Middle East Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ophthalmoplegia Market

• 29.1. Africa Ophthalmoplegia Market Overview
• 29.2. Africa Ophthalmoplegia Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ophthalmoplegia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ophthalmoplegia Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ophthalmoplegia Market Competitive Landscape And Company Profiles

• 30.1. Ophthalmoplegia Market Competitive Landscape
• 30.2. Ophthalmoplegia Market Company Profiles
  • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Medline Industries Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Ophthalmoplegia Market Other Major And Innovative Companies

• 31.1. Carl Zeiss AG
• 31.2. Bausch Health Companies Inc.
• 31.3. Sun Pharmaceutical Industries Limited
• 31.4. Bayer AG
• 31.5. Santen Pharmaceutical Co. Ltd.
• 31.6. Oculis Holding AG
• 31.7. Innovative Pharmaceuticals Pvt. Ltd.
• 31.8. Clearside Biomedical Inc.
• 31.9. Altacor Limited
• 31.10. Azura Ophthalmics Ltd.
• 31.11. ViGeneron GmbH
• 31.12. Amritt Inc.
• 31.13. GenSight Biologics SA
• 31.14. EyeBio Inc.
• 31.15. Opthea Limited

32. Global Ophthalmoplegia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ophthalmoplegia Market

34. Recent Developments In The Ophthalmoplegia Market

35. Ophthalmoplegia Market High Potential Countries, Segments and Strategies

• 35.1 Ophthalmoplegia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ophthalmoplegia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ophthalmoplegia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer